Episodic Digital Vasospasm - Is It Primary or Secondary?
- Raynaud's phenomenon is episodic VASOSPASM of the digital arteries triggered by COLD or EMOTIONAL stress, producing the classic TRIPHASIC colour change: WHITE (pallor from ischaemia) → BLUE (cyanosis from deoxygenation) → RED (rubor from reperfusion hyperaemia), with accompanying numbness, pain and tingling.
- The cardinal task is to separate PRIMARY Raynaud's (Raynaud's disease - no underlying cause) from SECONDARY Raynaud's (phenomenon - with an underlying cause). Primary disease is more common, affects younger WOMEN, is symmetrical and mild with no tissue loss, normal nailfold capillaries and negative autoimmune workup, and is benign.
- SECONDARY Raynaud's most often reflects a CONNECTIVE TISSUE DISEASE - SYSTEMIC SCLEROSIS is the commonest cause - but also SLE, mixed connective tissue disease and dermatomyositis; non-rheumatic causes include occupational hand-arm VIBRATION (vibration white finger), HYPOTHENAR HAMMER SYNDROME, drugs (beta-blockers, ergot, chemotherapy, stimulants), and haematologic/vascular disease.
- RED FLAGS for a secondary cause are: onset after age ~40, MALE sex, ASYMMETRIC attacks, SEVERE episodes with digital ULCERS/pitting/tissue loss, ABNORMAL nailfold capillaroscopy and POSITIVE autoantibodies or systemic features - these warrant rheumatology referral and a search for the cause.
- WORKUP: history (drugs, vibration/occupation, systemic symptoms) and examination (digital ulcers, sclerodactyly, telangiectasia, calcinosis), NAILFOLD CAPILLAROSCOPY (giant capillaries and reduced capillary density define a 'scleroderma pattern'), and autoantibodies (ANA, anti-centromere, anti-Scl-70) with inflammatory markers; an Allen's test and vascular assessment if a localised arterial cause is suspected.
- MANAGEMENT is a ladder: first CONSERVATIVE - keep the hands and body WARM (gloves, hand warmers), STOP SMOKING, avoid vasoconstrictors (non-selective beta-blockers, stimulants) and treat stress; first-line DRUG therapy is a dihydropyridine CALCIUM-CHANNEL BLOCKER (nifedipine/amlodipine), with PDE5 inhibitors (sildenafil), topical nitrates, ARBs or alpha-blockers as alternatives; for severe digital ischaemia/ULCERS (especially in systemic sclerosis) IV PROSTACYCLIN (iloprost) and endothelin antagonists (bosentan to prevent new ulcers) are used, and SURGERY (digital sympathectomy, botulinum toxin, or treating an underlying hypothenar hammer/embolic source) is reserved for refractory critical ischaemia.
- “Triphasic colour change: WHITE (ischaemia) → BLUE (cyanosis) → RED (reperfusion).
- “Primary = benign (young woman, symmetric, normal capillaroscopy, ANA-negative); Secondary = systemic sclerosis #1 (red flags: over 40, male, asymmetric, ulcers, abnormal capillaroscopy, +autoantibodies).
- “Ladder: warmth/stop smoking/avoid beta-blockers → CCB (nifedipine) first-line → PDE5/prostacyclin/bosentan for ulcers → surgery (digital sympathectomy) for refractory ischaemia. Exclude hypothenar hammer syndrome.
Primary or Secondary: Red Flags, Causes and Workup
Why the distinction matters. Primary Raynaud's (Raynaud's disease) has no underlying cause. It is common and benign, and needs no extensive workup when the picture is typical: a young woman with symmetrical, mild attacks and a normal examination. Primary disease causes no tissue loss, and the nailfold capillaries, ANA and inflammatory markers are normal. Reassure and treat conservatively.
Secondary Raynaud's (Raynaud's phenomenon) has an underlying cause and must be actively sought, because it can herald a serious systemic disease.
Red flags for a secondary cause. These warrant rheumatology referral and a search for the cause:
- Onset after about 40
- Male sex
- Asymmetric attacks
- Severe attacks with digital ulcers, pitting or gangrene
- Abnormal nailfold capillaroscopy
- Positive autoantibodies or systemic features
The causes.
- Connective tissue disease: systemic sclerosis (the commonest), SLE, mixed connective tissue disease, dermatomyositis and polymyositis
- Occupational and vascular: hand-arm vibration syndrome (vibration white finger), hypothenar hammer syndrome, thoracic outlet syndrome, atherosclerosis, emboli
- Drugs: beta-blockers, ergot, chemotherapy, sympathomimetics and stimulants
- Haematological: cryoglobulinaemia, polycythaemia
History and examination. Ask about drugs, occupation and vibration exposure, and systemic symptoms. Examine the hands for sclerodactyly, telangiectasia, calcinosis and ulcers.
Capillaroscopy and serology. Nailfold capillaroscopy looks for the scleroderma pattern, defined by giant capillaries and reduced capillary density. Serology is ANA and ENA (anti-centromere, anti-Scl-70), with inflammatory markers.
When Raynaud's is unilateral, affects only certain digits, or presents with digital ischaemia or ulcers, exclude a local arterial cause, especially hypothenar hammer syndrome (ulnar artery aneurysm or thrombosis at Guyon's canal from repetitive palmar trauma) and embolic sources. A hypothenar callus is a clue to repetitive-impact arterial injury. Exclude them with an Allen's test and vascular imaging (duplex or angiography).
These lesions are surgically treatable, and they are missed if every case is labelled 'Raynaud's'. (See Hypothenar Hammer Syndrome and Ulnar Tunnel Syndrome / Guyon's Canal.)
What the Tests Actually Buy You: Predicting Who Progresses
The real question. Capillaroscopy and autoantibodies are usually described as ways to classify a patient as primary or secondary. Their real value is prognostic. Raynaud's commonly precedes a connective tissue disease by years, so the first consultation asks whether there will be a disease, as well as whether there is one now.
The VEDOSS registry. The largest prospective answer comes from a multicentre registry that enrolled 1,150 patients presenting with Raynaud's phenomenon and no definable connective tissue disease; those followed were tracked for a median of 3.6 years. It assessed four features: ANA positivity, systemic-sclerosis-specific autoantibodies, abnormal nailfold capillaroscopy and puffy fingers.
- What happened
- Only 4 of 37 ANA-negative patients (10.8%) progressed - the strongest protective factor in the study
- What it means in clinic
- This is what licenses genuine reassurance rather than a label. A negative ANA is the single most useful result for the patient who wants to know whether this becomes something
- What happened
- 16 of 17 (94.1%) progressed - the highest-risk combination
- What it means in clinic
- Effectively a pre-clinical systemic sclerosis. Refer, do not observe
- What happened
- Progressively higher risk with each feature present
- What it means in clinic
- Stratify rather than dichotomise - risk is graded, not binary
- What happened
- 52.4% progressed
- What it means in clinic
- Note the denominator: these are patients referred with Raynaud's and at least one suspicious feature, not the general population of cold-sensitive hands
Puffy fingers. Diffuse, non-pitting swelling of the whole finger: the fingers look sausage-like and the skin creases are lost, before any true sclerodactyly has developed. It is an early scleroderma feature, easy to overlook, and it carries the most weight; with a systemic-sclerosis-specific antibody it was the highest-risk pairing in the registry. Look for it deliberately in anyone presenting with Raynaud's, and do not confuse it with the tapered, tight, shiny skin of established sclerodactyly, which is a later finding.
Do not over-read the headline figure. The 52.4% describes a referred cohort enriched for suspicious features. The clinically usable results are the extremes: ANA-negative is strongly reassuring, and a specific antibody with puffy fingers is near-certain progression.
Presentation and the Triphasic Colour Change
The attack. Raynaud's is episodic vasospasm of the digital arteries, provoked by cold or emotion. The colour change is usually well demarcated and affects the fingers, sparing the thumb in some. Numbness, tingling and pain accompany it, then throbbing on rewarming.
White, blue, red. The classic attack passes through three colours:
- White (pallor): the digital arteries go into spasm and the finger becomes ischaemic
- Blue (cyanosis): the static blood deoxygenates
- Red (rubor): the spasm resolves and reactive hyperaemia floods the finger
Not every patient shows all three phases, but the sharply demarcated pallor of digital ischaemia is the hallmark.
Management
The ladder. Management is a ladder, and every patient starts on the first rung:
- Conservative, for all patients. Keep the whole body and the hands warm (gloves, hand or pocket warmers, layered clothing), stop smoking, manage stress, and avoid vasoconstrictors: non-selective beta-blockers, ergotamine, sympathomimetics and stimulants.
- First-line drug. A dihydropyridine calcium-channel blocker, nifedipine or amlodipine, reduces the frequency and severity of attacks and is the most widely used agent.
- Second-line and alternatives. PDE5 inhibitors (sildenafil), topical nitrates, angiotensin-receptor blockers (losartan), alpha-blockers (prazosin) or SSRIs (fluoxetine).
- Severe disease and digital ulcers, especially in systemic sclerosis. IV prostacyclin (iloprost) for critical ischaemia and active ulcers, and the endothelin-receptor antagonist bosentan to reduce new digital ulcers.
- Refractory critical ischaemia. Surgery, including treatment of any underlying arterial lesion such as hypothenar hammer syndrome or an embolic source (below).
Why It Spasms - and Why the Drug Ladder Works
The imbalance. Raynaud's is an exaggerated vasoconstrictive response, from an imbalance between vasoconstriction and vasodilation. One mechanism ties the colour change to the vasoactive drugs used to treat it.
Neural. Cold and emotion drive sympathetic activity, and the digital vessels show increased alpha-2 adrenoceptor activity or sensitivity, particularly the cold-sensitive alpha-2C subtype. The result is excessive smooth-muscle constriction.
Endothelial. The endothelium is dysfunctional, with reduced nitric oxide and prostacyclin and increased endothelin-1, a potent vasoconstrictor.
Structural. In primary disease the spasm is functional and reversible, and the vessels are structurally normal. Secondary disease, systemic sclerosis for example, adds structural narrowing (intimal proliferation and fibrosis) and intravascular factors (platelet activation, raised viscosity), which is why secondary disease is more severe and ulcerates.
How the drugs map onto it. Calcium-channel blockers, topical nitrates and PDE5 inhibitors (via the nitric-oxide/cGMP pathway) are vasodilators. Iloprost replaces the deficient prostacyclin, bosentan blocks endothelin-1, and alpha-blockers oppose the adrenoceptor drive. Non-selective beta-blockers are avoided because unopposed alpha vasoconstriction worsens the spasm.
Surgery for Digital Ischaemia
Indications. Surgery is reserved for refractory critical digital ischaemia or non-healing ulcers despite maximal medical therapy.
The reconstructable lesion comes first. Exclude a localised arterial lesion before anything else. Hypothenar hammer syndrome (ulnar artery resection and reversed vein graft) or an embolic source is surgically curable; those reconstructions are covered in Hypothenar Hammer Syndrome.
Periarterial sympathectomy. Peripheral or digital (periarterial, Leriche) sympathectomy is a microsurgical stripping of the adventitia, and the sympathetic fibres travelling within it, from the radial and ulnar, common and proper digital arteries. Removing the sympathetic vasoconstrictor drive improves digital perfusion.
Botulinum toxin. Injected around the neurovascular bundles in the distal palm and digits, it is a less-invasive chemical sympatholysis that also reduces pain. The effect is temporary and repeatable.
The ulcer and the gangrene. Good wound care and treatment of infection come first. A dry distal gangrene may be allowed to auto-amputate (demarcate); wet or infected, or proximal, gangrene needs debridement or amputation at a demarcated level.
Mnemonics & Memory Aids
WBR
Hook:Raynaud's runs White → Blue → Red (WBR).
SECONDARY
Hook:SECONDARY lists the causes and red flags for secondary Raynaud's.
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“A patient describes their fingers going white then blue then red in the cold. How do you decide if this is primary or secondary Raynaud's, and why does it matter?”
“How would you manage a patient with troublesome Raynaud's, including one with digital ulcers from systemic sclerosis?”
Presentation
- Episodic digital vasospasm triggered by cold/emotion
- Triphasic colour: WHITE (ischaemia) → BLUE (cyanosis) → RED (reperfusion)
- Numbness/pain; well-demarcated pallor
Primary vs secondary
- Primary: young woman, symmetric, mild, normal capillaroscopy, ANA-negative (benign)
- Secondary causes: systemic sclerosis (#1), SLE/MCTD, vibration, HHS, drugs, haematologic
- Red flags: over 40/male, asymmetric, digital ulcers, abnormal capillaroscopy, +autoantibodies
Workup
- History (drugs/occupation), exam (sclerodactyly/telangiectasia/ulcers)
- Nailfold capillaroscopy (giant capillaries + reduced density = scleroderma pattern)
- ANA/ENA (anti-centromere, Scl-70) + markers; Allen's test/imaging if local cause
Management ladder
- Warmth, stop smoking, avoid beta-blockers/stimulants, stress management
- 1st-line: dihydropyridine CCB (nifedipine); then PDE5i/nitrates/ARB/alpha-blocker
- Digital ulcers (SSc): IV iloprost + bosentan; refractory: digital sympathectomy/botox; exclude HHS
Evidence & Key Studies
Progression of Raynaud's phenomenon to systemic sclerosis: the VEDOSS multicentre longitudinal registry
- 1,150 patients with Raynaud's phenomenon and no definable connective tissue disease enrolled across 42 centres; 553 followed for a median of 3.6 years, assessed on four criteria - ANA positivity, systemic-sclerosis-specific autoantibodies, abnormal nailfold capillaroscopy and puffy fingers.
- Absence of ANA at baseline was the strongest protective factor: only 4 of 37 ANA-negative patients (10.8%) progressed to fulfil classification criteria for systemic sclerosis.
- Systemic-sclerosis-specific autoantibodies together with puffy fingers carried the highest risk - 16 of 17 (94.1%) progressed.
- Overall progression among those reaching an endpoint or five years was 52.4%, but this is a referred cohort enriched for suspicious features rather than all patients with cold-sensitive fingers.
Sociodemographic and pharmacological characteristics of patients with primary and secondary Raynaud's phenomenon
- Of 567 patients (mean age 51.9 years, 82.5% women), 58.7% had primary and 41.3% secondary Raynaud's phenomenon.
- The most frequent secondary cause was systemic sclerosis (36.8%); calcium-channel blockers were the most used drugs (45.7%).
- 9.2% of patients were taking drugs that can worsen Raynaud's (mostly non-selective beta-blockers) - a reminder to review the drug history.
Evaluation of algorithms to identify the scleroderma pattern in nailfold videocapillaroscopy
- Nailfold videocapillaroscopy is well established in evaluating Raynaud's phenomenon and systemic sclerosis.
- Reduced capillary density (<=8 capillaries/mm) best identified the scleroderma pattern (accuracy ~88%), and giant capillaries were highly specific (~98%).
- Combining giant capillaries with low density gave high accuracy (~91%) - supporting capillaroscopy to distinguish secondary (scleroderma-pattern) from primary Raynaud's.
The primary/secondary proportions, systemic sclerosis as the main secondary cause, the predominance of calcium-channel blockers and the risk of beta-blockers worsening Raynaud's come from the cited Valladales-Restrepo study, and the role of nailfold capillaroscopy (giant capillaries, reduced density) in identifying the scleroderma pattern from the cited Shinzato study. The triphasic colour change, red flags and treatment ladder are standard, well-established teaching. The progression figures - the 10.8% in ANA-negative patients, the 94.1% with a specific autoantibody plus puffy fingers, and the 52.4% overall - come from the cited VEDOSS registry, and are quoted with their referred-cohort denominator because that is what makes them interpretable. The musculoskeletal manifestations of the disease those patients are progressing towards are developed in Systemic Sclerosis: Musculoskeletal Manifestations. (See also Hypothenar Hammer Syndrome, Ulnar Tunnel Syndrome / Guyon's Canal, Frostbite and Dermatomyositis and Polymyositis.)